Evoke Pharma, Inc. (EVOK)

Evoke Pharma Reports Second Quarter 2022 Financial Results

Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%SOLANA BEACH, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2022, and recent corporate developments. “Evoke delivered a solid second quarter based o

• 
  dentalcorp Reports Second Quarter 2022 Results

  CNW Group
• 
  ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022

  GlobeNewswire

Evoke Pharma to Report Second Quarter Results on August 10, 2022

SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022, after the market closes. Management will host a conference call on Wednesday, August 10, 2022, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 343-4849 and (203) 5

Evoke Pharma Recognizes Gastroparesis Awareness Month through its Support of The International Foundation for Gastrointestinal Disorders (IFFGD)

Ranked #1 in IFFGD Virtual Walk to spread awareness and support research for gastrointestinal disorders Evoke attending ANMS 2022 meeting August 5-7 in Philadelphia, PA SOLANA BEACH, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced their ongoing collaboration with the International Foundation for Gastrointestinal Disorders (IFFGD) for Gastroparesis Awareness Mo